MX2017000378A - ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS. - Google Patents
ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS.Info
- Publication number
- MX2017000378A MX2017000378A MX2017000378A MX2017000378A MX2017000378A MX 2017000378 A MX2017000378 A MX 2017000378A MX 2017000378 A MX2017000378 A MX 2017000378A MX 2017000378 A MX2017000378 A MX 2017000378A MX 2017000378 A MX2017000378 A MX 2017000378A
- Authority
- MX
- Mexico
- Prior art keywords
- improved
- antibodies
- binding antibodies
- relate
- protofibril binding
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000004845 protein aggregation Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Abstract
La presente invención se refiere a el péptido beta amiloide (Aß) y más específicamente a anticuerpos de unión a protofibrillas Aß y su uso en terapia y/o tratamiento profiláctico de enfermedad de Alzheimer y otros trastornos asociados a la agregación de proteína Aß; además la invención puede referirse al diagnóstico de dichas enfermedades así como monitoreo del avance de la enfermedad mediante el uso de los anticuerpos de la invención; además, la invención puede referirse al uso veterinario de los anticuerpos de la invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462022952P | 2014-07-10 | 2014-07-10 | |
PCT/EP2015/065633 WO2016005466A2 (en) | 2014-07-10 | 2015-07-08 | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017000378A true MX2017000378A (es) | 2017-08-25 |
Family
ID=53673920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000378A MX2017000378A (es) | 2014-07-10 | 2015-07-08 | ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS. |
Country Status (33)
Country | Link |
---|---|
US (1) | US9573994B2 (es) |
EP (2) | EP3166970B1 (es) |
JP (1) | JP6628786B2 (es) |
KR (2) | KR20230129449A (es) |
CN (2) | CN106661103B (es) |
AR (1) | AR101130A1 (es) |
AU (1) | AU2015286707B2 (es) |
BR (1) | BR112016030774A2 (es) |
CA (1) | CA2951990C (es) |
CL (1) | CL2017000053A1 (es) |
CO (1) | CO2017000346A2 (es) |
CY (1) | CY1124563T1 (es) |
DK (1) | DK3166970T3 (es) |
ES (1) | ES2865112T3 (es) |
HR (1) | HRP20210680T1 (es) |
HU (1) | HUE053809T2 (es) |
IL (2) | IL282823B1 (es) |
JO (1) | JO3537B1 (es) |
LT (1) | LT3166970T (es) |
MA (2) | MA53887A (es) |
MX (1) | MX2017000378A (es) |
MY (1) | MY184890A (es) |
PE (1) | PE20170768A1 (es) |
PH (1) | PH12017500032A1 (es) |
PL (1) | PL3166970T3 (es) |
PT (1) | PT3166970T (es) |
RS (1) | RS61717B1 (es) |
RU (1) | RU2700104C2 (es) |
SG (1) | SG11201610734RA (es) |
SI (1) | SI3166970T1 (es) |
TW (1) | TWI678376B (es) |
WO (1) | WO2016005466A2 (es) |
ZA (1) | ZA201706272B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107849125A (zh) | 2015-07-21 | 2018-03-27 | 生命北极神经科学公司 | 用于治疗靶向聚集的肽的创伤性脑损伤的方法 |
BR112019000098A2 (pt) * | 2016-07-14 | 2019-04-09 | Bioarctic Ab | proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio |
SG10201913049QA (en) * | 2016-10-27 | 2020-02-27 | Eisai R&D Man Co Ltd | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
CN112805031A (zh) | 2018-07-24 | 2021-05-14 | 卫材R&D管理有限公司 | 阿尔茨海默病的治疗及预防方法 |
JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗aベータ抗体 |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
IL309468A (en) | 2021-07-09 | 2024-02-01 | Eisai R&D Man Co Ltd | Biomarkers for the treatment of Alzheimer's disease |
AU2022338055A1 (en) | 2021-08-30 | 2024-02-29 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
WO2023149970A1 (en) | 2022-02-02 | 2023-08-10 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
CN114578066B (zh) * | 2022-05-07 | 2022-08-19 | 北京第一生物化学药业有限公司 | 检测β-淀粉样蛋白的产品和方法 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
US6174916B1 (en) | 1990-04-27 | 2001-01-16 | Milkhaus Laboratory, Ltd. | Methods for treating herpes virus infections |
JP2980677B2 (ja) | 1990-04-27 | 1999-11-22 | マクマイケル,ジョン | 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物 |
US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
ATE198622T1 (de) | 1993-10-27 | 2001-01-15 | Elan Pharm Inc | Transgene tiere, die app allele mit der schwedischen mutation beherbergen |
AU686818B2 (en) | 1994-05-25 | 1998-02-12 | John Mcmichael | Materials and methods for treatment of plaquing diseases |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US6303567B1 (en) | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
CA2214247C (en) | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
US5985242A (en) | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
JPH09178743A (ja) | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | 可溶性appの定量法 |
US6054114A (en) | 1996-05-08 | 2000-04-25 | Massachusetts Institute Of Technology | Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro |
US20060178302A1 (en) | 1997-02-05 | 2006-08-10 | Northwestern University & The University Of Southern California | Amyloid beta protein (globular assembly and uses thereof) |
US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
ATE306931T1 (de) | 1997-12-03 | 2005-11-15 | Neuralab Ltd | Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer |
WO2000039310A1 (en) | 1998-12-29 | 2000-07-06 | The University Of Georgia Research Foundation, Inc. | Rubredoxin fusion proteins, protein expression system and methods |
US6670195B1 (en) | 1999-05-26 | 2003-12-30 | New York University | Mutant genes in Familial British Dementia and Familial Danish Dementia |
AR024558A1 (es) | 1999-06-01 | 2002-10-16 | Neuralab Ltd | Composiciones del peptido a-beta y procesos para producir las mismas |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
CA2378953A1 (en) | 1999-07-27 | 2001-02-01 | Abgenix, Inc. | Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
CA2381323C (en) | 1999-08-04 | 2009-10-06 | University Of Southern California | Amyloid .beta. protein (globular assembly and uses thereof) |
KR20080059676A (ko) | 1999-11-29 | 2008-06-30 | 뉴로겜 인터내셔널 리미티드 | 알츠하이머 및 아밀로이드 관련 질병의 예방 및 치료용백신 |
EP1284998B1 (en) | 2000-05-22 | 2004-12-29 | New York University | Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits |
EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
US20030187011A1 (en) | 2001-12-20 | 2003-10-02 | Lashuel Hilal A. | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease |
MXPA04010255A (es) | 2002-04-19 | 2008-03-04 | Univ Toronto | Metodos inmunologicos y composiciones para el tratamiento de la enfermedad de alzheimier. |
US20040049134A1 (en) | 2002-07-02 | 2004-03-11 | Tosaya Carol A. | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain |
US8871447B2 (en) | 2002-09-12 | 2014-10-28 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
WO2004031400A2 (en) | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
AU2003285151A1 (en) | 2002-11-04 | 2004-06-07 | Bioarctic Neuroscience Ab | Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US20050124016A1 (en) | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
EP1668369B1 (en) | 2003-08-20 | 2016-01-06 | ProMIS Neurosciences Inc. | Epitope protection assay and method for detecting protein conformations |
JP2007527865A (ja) | 2003-09-12 | 2007-10-04 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体 |
SE0400707D0 (sv) | 2004-03-22 | 2004-03-22 | Bioarctic Neuroscience Ab | Transgenic animal model |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
JP2008513732A (ja) | 2004-07-02 | 2008-05-01 | ノースウエスタン ユニバーシティ | アミロイドβ(Abeta)の病理学的なアセンブリを標的とするモノクローナル抗体 |
US20060079447A1 (en) * | 2004-10-08 | 2006-04-13 | Wetzel Ronald B | Stabilized A-beta protofibrillar aggregates |
WO2006047254A1 (en) | 2004-10-22 | 2006-05-04 | Regents Of The University Of Minnesota | Assemblies of oligomeric amyloid beta protein and uses thereof |
CA2584859C (en) * | 2004-10-25 | 2017-11-07 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
US20060240486A1 (en) | 2004-12-15 | 2006-10-26 | Johnson-Wood Kelly L | Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
US20110020237A1 (en) | 2005-01-14 | 2011-01-27 | Glabe Charles G | Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
US7731962B2 (en) | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
KR20080021585A (ko) | 2005-03-05 | 2008-03-07 | 애보트 게엠베하 운트 콤파니 카게 | 스크리닝 방법, 비확산성 a-베타 올리고머의 정제 방법,당해 비확산성 a-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법 |
US7741448B2 (en) | 2005-06-21 | 2010-06-22 | Medical & Biological Laboratories Co., Ltd. | Antibody having inhibitory effect on amyloid fibril formation |
TW200726482A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
JP5289963B2 (ja) | 2005-10-21 | 2013-09-11 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗addlモノクローナル抗体およびその使用 |
WO2007062088A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of alzheimer's and related diseases |
KR101413615B1 (ko) * | 2006-03-23 | 2014-07-18 | 바이오악틱 뉴로사이언스 에이비 | 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도 |
UA100672C2 (en) * | 2006-07-14 | 2013-01-25 | Ас Иммуне Са | HUMANIZED ANTIBODY TO b-AMYLOID PROTEIN |
TWI608014B (zh) * | 2006-07-14 | 2017-12-11 | Ac免疫公司 | 抗β-類澱粉抗體或其抗原結合片段、其用途及使用方法 |
KR20150002879A (ko) * | 2006-10-02 | 2015-01-07 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
BRPI0815399A2 (pt) * | 2007-08-13 | 2019-09-24 | Vasgene Therapeutics Inc | tratamento de câncer usando anticorpos humanizados que se ligam ephb4 |
EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
JP5616230B2 (ja) | 2007-11-16 | 2014-10-29 | ザ ロックフェラー ユニバーシティー | ベータ−アミロイドタンパク質のプロトフィブリルの形態に特異的な抗体 |
JP5747414B2 (ja) | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
ES2932874T3 (es) | 2009-03-25 | 2023-01-27 | Genentech Inc | Anticuerpos anti-FGFR3 y métodos que utilizan los mismos |
US20120100129A1 (en) | 2009-06-29 | 2012-04-26 | Gellerfors Paer | N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders |
WO2011016568A1 (ja) * | 2009-08-07 | 2011-02-10 | 協和発酵キリン株式会社 | 抗アミロイドβオリゴマーヒト化抗体 |
CN106397588B (zh) * | 2010-02-26 | 2020-09-08 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
CA2806252C (en) * | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Antibodies with modified isoelectric points |
WO2012083370A1 (en) | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
-
2015
- 2015-07-08 EP EP15738876.0A patent/EP3166970B1/en active Active
- 2015-07-08 MY MYPI2017700010A patent/MY184890A/en unknown
- 2015-07-08 US US14/794,172 patent/US9573994B2/en active Active
- 2015-07-08 SI SI201531593T patent/SI3166970T1/sl unknown
- 2015-07-08 MA MA053887A patent/MA53887A/fr unknown
- 2015-07-08 MX MX2017000378A patent/MX2017000378A/es unknown
- 2015-07-08 IL IL282823A patent/IL282823B1/en unknown
- 2015-07-08 ES ES15738876T patent/ES2865112T3/es active Active
- 2015-07-08 LT LTEP15738876.0T patent/LT3166970T/lt unknown
- 2015-07-08 CN CN201580036189.2A patent/CN106661103B/zh active Active
- 2015-07-08 EP EP21154511.6A patent/EP3865510A3/en active Pending
- 2015-07-08 DK DK15738876.0T patent/DK3166970T3/da active
- 2015-07-08 RS RS20210459A patent/RS61717B1/sr unknown
- 2015-07-08 CA CA2951990A patent/CA2951990C/en active Active
- 2015-07-08 AU AU2015286707A patent/AU2015286707B2/en active Active
- 2015-07-08 HU HUE15738876A patent/HUE053809T2/hu unknown
- 2015-07-08 CN CN202011054114.6A patent/CN112390881A/zh active Pending
- 2015-07-08 TW TW104122215A patent/TWI678376B/zh active
- 2015-07-08 JP JP2017500897A patent/JP6628786B2/ja active Active
- 2015-07-08 RU RU2017103446A patent/RU2700104C2/ru active
- 2015-07-08 BR BR112016030774-7A patent/BR112016030774A2/pt active Search and Examination
- 2015-07-08 PL PL15738876T patent/PL3166970T3/pl unknown
- 2015-07-08 WO PCT/EP2015/065633 patent/WO2016005466A2/en active Application Filing
- 2015-07-08 JO JOP/2015/0167A patent/JO3537B1/ar active
- 2015-07-08 AR ARP150102178A patent/AR101130A1/es unknown
- 2015-07-08 PE PE2017000024A patent/PE20170768A1/es unknown
- 2015-07-08 MA MA40224A patent/MA40224B1/fr unknown
- 2015-07-08 SG SG11201610734RA patent/SG11201610734RA/en unknown
- 2015-07-08 KR KR1020237024350A patent/KR20230129449A/ko not_active Application Discontinuation
- 2015-07-08 KR KR1020167037100A patent/KR102564384B1/ko active IP Right Grant
- 2015-07-08 PT PT157388760T patent/PT3166970T/pt unknown
-
2017
- 2017-01-05 PH PH12017500032A patent/PH12017500032A1/en unknown
- 2017-01-09 IL IL250001A patent/IL250001B/en active IP Right Grant
- 2017-01-09 CL CL2017000053A patent/CL2017000053A1/es unknown
- 2017-01-13 CO CONC2017/0000346A patent/CO2017000346A2/es unknown
- 2017-09-15 ZA ZA2017/06272A patent/ZA201706272B/en unknown
-
2021
- 2021-04-29 HR HRP20210680TT patent/HRP20210680T1/hr unknown
- 2021-06-01 CY CY20211100477T patent/CY1124563T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500032A1 (en) | Improved a� protofibril binding antibodies | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
MX2019012233A (es) | Anticuerpos anti-sirpa. | |
SA519410311B1 (ar) | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها | |
WO2017030823A3 (en) | Anti-tigit antibodies | |
MX2018008557A (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos. | |
WO2014176128A3 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
MX2015015249A (es) | Peptidos terapeuticos. | |
MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
MX2022015250A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
MX2019006495A (es) | Tratamiento de enfermedades neurologicas. | |
WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
PH12019500434A1 (en) | Anti-gm-csf antibodies and uses thereof | |
MX2016016491A (es) | Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas. | |
GB201904810D0 (en) | The treatment of protein aggregation diseases |